Dr. Sandhu on the Safety Data Seen in the MAGNITUDE Trial in Prostate Cancer

Shahneen Sandhu, MD, associate professor, consultant medical oncologist, researcher, melanoma and uro-oncology units, Peter MacCallum Cancer Centre, discusses the safety data seen in the phase 3 MAGNITUDE trial (NCT03748641) in metastatic prostate cancer.

The phase 3 trial is assessing the safety and efficacy of niraparib (Zejula) in combination with abiraterone acetate (Zytiga) plus prednisone compared with abiraterone acetate plus prednisone and placebo in patients with metastatic prostate cancer.

The activity and safety of niraparib and abiraterone as single agents is well defined, and the adverse effects associated with the combination of these agents has proven manageable, Sandhu explains. In the phase 3 MAGNITUDE trial, no new safety signals arose with the combination, Sandhu adds.

At the 2022 ASCO Annual Meeting, additional data was presented from the trial, showing that quality of life was maintained with the niraparib regimen, Sandhu concludes.